Introduction
============

TGF-β is a potent immune regulator, controlling the differentiation, function, and survival of hemopoietic cells including B- and T-cells ([@B1]). Control of B-cell homeostasis is mediated through the TGF-β-dependent regulation of cell cycle arrest and apoptosis. We have previously shown that TGF-β signaling contributes to "death by neglect" of spontaneously apoptosing human germinal center centroblasts, as well as inducing apoptosis of malignant lymphomas derived from the germinal center B-cells (c-Myc transformed Burkitt\'s lymphoma (BL)[^5^](#FN5){ref-type="fn"} cells) ([@B2], [@B3]). This apoptosis program is induced by the intracellular signaling cascades activated by the binding of TGF-β to the high affinity TGF-β type II receptor. Binding of ligand to the TGF-β type II receptor enables the formation of a heterotetrameric complex between the constitutively active serine/threonine kinase type II receptor and the type I receptor, ALK5. The TGF-β type II receptor phosphorylates and activates ALK5, thereby inducing the canonical Smad pathway and/or several non-Smad pathways ([@B4], [@B5]). ALK5 activation results in C-terminal phosphorylation of the receptor-regulated Smads, Smad2 (Ser-465/476) and Smad3 (Ser-433/435), which then bind to the co-Smad, Smad4. The resulting heteroligomeric Smad complexes accumulate within the nucleus to control expression of genes involved in the regulation of cell survival and apoptosis ([@B6]).

In BL cells, TGF-β-induced apoptosis is associated with changes in expression levels of apoptosis regulators upstream of BAX and BAK. Activated BAX and BAK homo-oligomerize in the mitochondrial membrane to cause mitochondrial outer membrane permeabilization ([@B7]) and the release of pro-apoptotic factors. The function of BAX and BAK is tightly regulated by the BCL-2 family of proteins, including the pro-survival factors BCL-2 and its homologues, BCL-X~L~, MCL-1, BFL-1, BOO, and BCL-w. Other members of the family share one region of homology with BCL-2 (BH3-only proteins), are pro-apoptotic, and include BIK, PUMA, BID, NOXA, BIM, BAD, HRK, and BMF. The "activators" of BAX and BAK ([@B8]) include BIM, tBID, and PUMA ([@B8]--[@B10]), which are proposed to directly bind to BAX and BAK in response to apoptotic stimuli. The pro-survival factors such as BCL-2 prevent apoptosis by sequestering the activator proteins, but they themselves may be inhibited by selective interaction with BH3-only proteins ([@B11]). These proteins are therefore referred to as apoptosis "sensitizers," which may either liberate activators from the pro-survival factors to enable BAX/BAK activation ([@B12]) or, alternatively, block the direct interaction of pro-survival factors with BAX and BAK ([@B13]).

Of these BCL-2 family members, TGF-β induces Smad-dependent transcription of the sensitizer BIK and down-regulation of the pro-survival factor BCL-X~L~ in BL cells ([@B3]), however, no regulation of the activators BIM or tBID was evident during initiation of the apoptosis program. PUMA ([p]{.ul}53-[u]{.ul}p-regulated [m]{.ul}odulator of [a]{.ul}poptosis) is therefore the only other direct BAX/BAK activator that may have a role in promoting TGF-β-induced apoptosis in this system. PUMA physically associates with BAX via its BH3 domain (residues 127--150) to induce an apoptotic change in conformation of BAX ([@B10]), as well as promoting BAX-dependent apoptosis by dissociating BCL-X~L~ from BAX ([@B10], [@B14]). *PUMA* is transcriptionally regulated by the p53 family ([@B15]--[@B17]), NF-κB ([@B18]), and E2F-1 ([@B19]), by activated FOXO3a following cytokine withdrawal ([@B20]) and in response to calcium pool depletion of the endoplasmic reticulum ([@B21]).

The tumor suppressor functions of p53 are rate-limiting for lymphomagenesis in Eμ-*Myc* murine models of BL. PUMA plays a major role in both p53-mediated and p53-independent cell death ([@B22], [@B23]) and is required for oncogene-induced cell death caused by c-Myc overexpression ([@B22], [@B24]). Consequently, genetic deletion of *Puma* accelerates the development of Eμ-*Myc* lymphomas ([@B24]), and the p53/PUMA pathway is often disrupted in Eμ-*Myc* and BL lymphomas, either by mutation or silencing of p53, by disruption of key p53 regulators (p19^ARF^ and MDM2) ([@B25]), or by epigenetic silencing of *PUMA* itself ([@B24]). PUMA is also elevated in activated human and murine primary B-cells and is involved in the regulation of mature B-cell survival following T-cell-dependent B-cell response to antigen ([@B26]).

Because activation of PUMA effectively limits lymphomagenesis, in this study we investigate whether PUMA is a downstream effector of TGF-β-induced apoptosis of human and murine c-Myc driven lymphomas. We identify *PUMA* as a novel direct target of TGF-β signaling in B-cells that mediates rapid induction of apoptosis in response to TGF-β.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Cell Lines and Reagents

BL cell lines were maintained in RPMI 1640 (Invitrogen) supplemented with 5--10% (v/v) heat-inactivated FCS, 2 m[m]{.smallcaps} glutamine, and antibiotics. Murine Eμ-*Myc* lymphoma lines were generated as detailed previously ([@B27]) and maintained in DMEM (Invitrogen) supplemented with 10% heat-inactivated FCS, 2 m[m]{.smallcaps} glutamine (Invitrogen), 1 m[m]{.smallcaps} pyruvate (Invitrogen), 50 μ[m]{.smallcaps} β-mercaptoethanol (Sigma), 200 μ[m]{.smallcaps} asparagine (Sigma), and antibiotics. Analyses were performed on four cell lines derived from four independent Eμ-*Myc* lymphomas isolated from *Puma*^+/+^ mice and on four cell lines derived from four independent Eμ-*Myc* lymphomas isolated from *Puma*^−/−^ mice. The cells were treated as required with 1--5 ng/ml TGF-β1 (Peprotech), 50 μ[m]{.smallcaps} Z-VAD.FMK (Calbiochem), 5 μg/ml etoposide (Sigma), or 10 μ[m]{.smallcaps} SB-431542 (Tocris). Protein synthesis inhibition was carried out by preincubation for 2 h with 50 μg/ml cycloheximide and 100 μ[m]{.smallcaps} anisomycin (Sigma). Inhibition of transcription was carried out by pretreatment of cells for 1 h with 2.5 μg/ml actinomycin D (Sigma). Inhibition of c-Myc activity was carried out by treatment of cells with 25 μ[m]{.smallcaps} of the c-Myc selective inhibitor 10058-F4 (5-\[(4-ethylphenyl) methylene\]-2-thioxo-4-thiazolidinone) (Sigma).

#### Transient Transfection of CA46 BL Cells

5 × 10^6^ CA46 BL cells were transfected in triplicate with 3 μg of firefly luciferase reporter plasmid and 1 μg of *Renilla* luciferase or β-galactosidase expression plasmids as internal controls for transfection efficiency using an Amaxa nucleofector (solution T, program A-23) as recommended by the manufacturer. Treatment with SB-431542 (10 μ[m]{.smallcaps}) or solvent vehicle was carried out after transfection if required. Transfected cells were incubated overnight before being treated with TGF-β (5 ng/ml) for 6 h. The ratio of firefly/*Renilla* luciferase activity was determined using the dual luciferase assay system (Promega) and expressed as the means ± S.D. ratio relative to untreated control samples. The Smad4 shRNA plasmid (TRC 40028) was obtained from Open Biosystems.

#### Isolation of Centroblasts

CD77+ve cells were purified as described previously ([@B3]). Following isolation, the cells were incubated with or without TGF-β in the presence of z-VAD-fmk.

#### Immunoblotting and Antibodies

Radioimmune precipitation assay lysates were analyzed by SDS-PAGE. Antibodies used in Western blotting were mouse monoclonals against PARP (BD Biosciences); Smad2/3 (BD Biosciences); actin (Sigma); rabbit polyclonal antibodies recognizing phospho-Smad 2 (Ser-465/476), phospho-Smad3 (Ser-433/435), and PUMA (Cell Signaling/Enzo Life Sciences); and a rabbit monoclonal against Tubulin (Cell Signaling). Secondary HRP-conjugated antibodies were obtained from Dako/GE Biosciences. Bound immunocomplexes were detected by enhanced chemiluminescence (ECL; Amersham Biosciences) or Immobilon western chemiluminescent substrate (Millipore).

#### Analysis of Apoptosis by Flow Cytometry

The cells were fixed in 80% ethanol, labeled with propidium iodide and analyzed by flow cytometry for less than 2 [n]{.smallcaps} DNA content. Murine lymphoma lines were stained with FITC-conjugated annexin V (1 μg/ml, kindly provided by Dr. P. Duriez) and propidium iodide (5 μg/ml) in binding buffer (10 m[m]{.smallcaps} HEPES, pH 7.4, 140 m[m]{.smallcaps} NaCl, 2.5 m[m]{.smallcaps} CaCl~2~) and analyzed by flow cytometry.

#### Lentiviral Infection of BL Cell Lines

HEK293FT cells were co-transfected with lentiviral packaging plasmids and pLKO.1-based shRNA constructs (TRC 33610 or TRC 33613; Open Biosystems, termed sh1 and sh2). Lentivirus-containing supernatants were collected, filtered, pooled, and used to infect BL cells. After 48 h, the cells were selected in 0.4 μg/ml puromycin. The resulting stably transduced BL30 cells were routinely passaged in growth medium (RPMI 1640 plus 20% FCS) containing 0.6 μg/ml puromycin. Experiments to analyze TGF-β-induced apoptosis were carried out in the absence of selection medium.

#### Retroviral Infection of Murine Eμ-Myc Lymphoma Lines

Ecotropic Phoenix cells were treated with 5 μ[m]{.smallcaps} chloroquine 30 min prior to calcium: phosphate precipitation-mediated transfection with the pMIH vector (modified pMIG, GFP cassette exchanged for hygromycin resistance) encoding a human BCL-2 transgene, or vector alone, alongside the helper vector pCL.Eco. After 48 h, virus-containing supernatants were removed and filtered, and Polybrene was added to 4 μg/ml. Eμ-*Myc* lymphomas were plated at 6 × 10^5^ cells/well in a 12-well plate, and 1.5 ml of virus-containing medium was applied. The plates were centrifuged at 480 × *g* at 37 °C for 45 min. Selection was then carried out using 250 μg/ml hygromycin for 7 days. Subsequently, BCL-2 expression levels were analyzed by flow cytometry and Western blot.

#### qRT-PCR

Total cell RNA was isolated using TRIzol as recommended by the manufacturer. cDNA and qRT-PCRs were prepared using SYBR green two-step qRT-PCR kits (Finnzymes) and specific primers for each gene (Qiagen). Amplified products were analyzed by Chromo4 continuous fluorescence detector and Opticon Monitor3 software. The relative amount of RNA for each gene is expressed after normalization to the amount of 18 S rRNA in each sample. RNA isolated from murine lymphomas was converted to cDNA using a first strand synthesis RT-PCR kit (Invitrogen). Quantitative PCRs were performed using qPCR Supermix-UND (Invitrogen) and TaqMan gene-specific primers (Applied Biosystems). Amplification and analysis was achieved via use of a C1000 thermal cycler fitted with a CFX96 fluorescence detector (Bio-Rad) and CFX96 manager software (Bio-Rad).

#### ChIP Assay

2 × 10^7^ CA46 cells were treated with 1 ng/ml TGF-β for 1 h and fixed in 1% formaldehyde for 15 min. The formaldehyde was quenched with glycine, the cells were washed in PBS, and nuclear extracts were prepared. The extracts were sonicated to fragment the DNA and incubated overnight with 20 ng of goat anti-Smad3 or 4 (Santa Cruz) or isotype-matched control antibodies. Immune complexes were captured using anti-goat IgG-coated agarose beads, the samples were washed, and the DNA was eluted off the beads. DNA cross-links were reversed by incubation at 65 °C in 0.3 [m]{.smallcaps} NaCl, and the samples were then digested with proteinase K. DNA was extracted using phenol/chloroform and ethanol-precipitated. PCRs using specific primers for human *PUMA* (5′-AGACTTGCTTGAACCCAGGA-3′ and 5′-AATCGCCTCACCAGAGTGAC-3′) were performed for 35--50 cycles, and the PCR products were analyzed on 2% agarose gels stained with SYBR Green.

RESULTS
=======

### 

#### TGF-β Induces the BH3-only Activator PUMA

We previously showed that TGF-β treatment of BL cells results in the transcriptional regulation of members of the BCL-2 family of apoptosis regulators including BIK and BCL-X~L~ ([@B3]). Analysis of other BH3-only proteins that might contribute to the apoptotic program induced by TGF-β was carried out on subsequent TGF-β treatment time courses ([Fig. 1](#F1){ref-type="fig"}). Apoptosis was evident, as detected by Western blotting for cleavage of the caspase-3 substrate PARP, as early as 6--8 h after TGF-β addition ([Fig. 1](#F1){ref-type="fig"}*A*). During this period, the induction of BIK mRNA was confirmed; however, we also detected a transient increase in transcripts of the apoptosis activator *PUMA* ([Fig. 1](#F1){ref-type="fig"}*B*). There was no concurrent increase in expression levels of the apoptosis sensitizers, *NOXA*, *BAD*, *HRK*, or *BMF*. The induction of *PUMA* mRNA in response to exogenous TGF-β addition was confirmed across a panel of BL cell lines ([Fig. 2](#F2){ref-type="fig"}*A*) and at the level of protein expression ([Fig. 2](#F2){ref-type="fig"}*B*). The Western blot analysis shown in [Fig. 2](#F2){ref-type="fig"}*B* indicates that the α isoform but not the β isoform of PUMA was induced in response to TGF-β signaling.

![**Transcripts of *PUMA* and *BIK* are elevated in TGF-β-treated Ramos BL cells.** *A*, time course of TGF-β-induced apoptosis in human BL cells (Ramos). The cells were treated with 1 ng/ml TGF-β for the times indicated. Radioimmune precipitation assay lysates were analyzed by Western blotting for TGF-β signaling (phosphorylation of Smad2 and Smad3) and apoptosis (cleavage of PARP). A Western blot for total Smad2/3 is included as a loading control. *B*, quantitative real time qRT-PCR analysis of BH3-only members of the BCL-2 family in TGF-β-treated Ramos cells. The mean (± S.D.) fold increases relative to untreated cells (set at 1) are shown.](zbc0101338940001){#F1}

![**PUMA is induced by TGF-β in human BL cell lines and in normal tonsil CD77-positive B-cells.** *A*, real time qRT-PCR analysis of *PUMA* in a panel of TGF-β responsive BL cell lines following 2 h of treatment. The mean (± S.D.) fold increase above background (set at 1 in untreated cells) is shown. *B*, Western blot analysis of radioimmune precipitation assay extracts from BL cells either untreated or treated with TGF-β for 2--8 h. Immunoreactive bands showing both the TGF-β-inducible PUMA-α (23 kDa) and PUMA-β isoforms are indicated. A Western blot for total Smad2/3 is included as a loading control. *C* and *D*, real time qRT-PCR analysis of RNA isolated from human primary CD77-positive tonsil B-cells treated with z-VAD.FMK and TGF-β for 2 h (*C*) and over an extended 24-h time course of TGF-β treatment (*D*). The mean (± S.D.) fold TGF-β-induced increase in normalized RNA expression compared with untreated cells (set at 1) is shown (*C*). The mean (± S.D.) relative levels of *PUMA* RNA normalized to 18 S are shown in *D*.](zbc0101338940002){#F2}

BLs are derived from centroblasts within the germinal centers of secondary lymphoid tissue. By isolating CD77-positive centroblasts from human tonsil tissue (as described in Ref. [@B3]), we were able to demonstrate a small but consistent increase in *PUMA* mRNA expression in TGF-β treated cells relative to untreated controls. No comparable increase in either *NOXA* or *HRK* mRNA expression was evident ([Fig. 2](#F2){ref-type="fig"}*C*). Increased abundance of *PUMA* RNA transcripts in the presence of TGF-β was also evident throughout a 24-h time course of treatment of CD77-positive primary cells ([Fig. 2](#F2){ref-type="fig"}*D*). *PUMA* can therefore be induced in response to TGF-β in both BL cell lines and in the cell of origin isolated from primary tissue. Induction of *PUMA* mRNA in response to exogenous TGF-β addition could also be detected in the pro-B-cell line RS4;11, but not in non-B-cell lineages including mouse embryo fibroblasts and HaCaT epithelial cells (data not shown).

#### PUMA Is a Direct Target Gene of TGF-β Signaling in Human B-cells

We next investigated the mechanism of TGF-β-mediated regulation of *PUMA* expression first by testing whether *PUMA* is an immediate early target of TGF-β signaling. BL cells were pretreated with cycloheximide and anisomycin and were subsequently treated with exogenous TGF-β for the times indicated. Induction of *PUMA* occurred even in the absence of *de novo* protein synthesis ([Fig. 3](#F3){ref-type="fig"}*A*), but blocking transcription with actinomycin D resulted in the complete ablation of *PUMA* mRNA induction ([Fig. 3](#F3){ref-type="fig"}*B*). c-Myc overexpression is characteristic of BL cells, and c-Myc itself is known to repress *PUMA* transcription following growth factor stimulation ([@B28]). We tested the effect of c-Myc overexpression on TGF-β-induced activation of *PUMA* by pretreating BL cells with the c-Myc inhibitor 10058-F4 at concentrations previously shown to induce BL cell death ([@B29]). Inhibition of c-Myc modestly increased basal *PUMA* transcription (especially in L3055 cells) but did not significantly affect *PUMA* induction in response to TGF-β ([Fig. 3](#F3){ref-type="fig"}*C*). Our data indicate that *PUMA* is a direct target of TGF-β signaling and, as such, implies that *PUMA* transcription is likely to be regulated by Smad complexes binding to a cognate binding element within the gene promoter. Smad-binding regions (SBRs) frequently contain two copies of the Smad-binding element (SBE) sequence 5′-GTCT-3′ or its reverse complement 5′-AGAC-3′ ([@B30]). We identified a potential SBR (5′-**agac**tct**gtct**-3′) ([Fig. 3](#F3){ref-type="fig"}*D*) ∼1.9 kb upstream of the *PUMA* transcription start site, contained within a region of the promoter bearing striking homology to the SBR we previously identified within the human *BIK* promoter ([Fig. 3](#F3){ref-type="fig"}*D* and Ref. [@B3]). ChIP analysis using primers spanning this region demonstrated TGF-β-dependent binding of Smads 3 and 4 to the endogenous *PUMA* promoter *in vivo* ([Fig. 3](#F3){ref-type="fig"}*E*).

![**TGF-β directly regulates *hPUMA* transcription and induces recruitment of activated Smad complexes to the *hPUMA* promoter.** *A*, real time qRT-PCR for *PUMA* expression in CA46 cells treated with or without TGF-β and the protein synthesis inhibitors cycloheximide and anisomycin (*C+A*) as indicated. The cells were pretreated with cycloheximide and anisomycin for 2 h, and TGF-β was added at 0 h. The mean (± S.D.) *PUMA* RNA expression levels relative to the 2-h untreated sample is shown (2-h untreated sample value was set at 1). The fold induction relative to the untreated sample at each time point is shown. *B*, real time qRT-PCR for *PUMA* expression in CA46 cells untreated or pretreated for 1 h with the transcription inhibitor actinomycin D (*ActD*), followed by a time course of TGF-β treatment. RNA expression is expressed relative to the levels detected in the 2-h untreated sample (assigned a value of 1). *C*, a panel of BL cell lines was pretreated for 30 min with 25 μ[m]{.smallcaps} of the c-Myc inhibitor (*Myc i*) 10058-F4 followed by 2 h of TGF-β treatment (1 ng/ml). RNA was extracted and analyzed by qPCR for *PUMA* expression. Expression levels were normalized to the internal standard 18 S RNA and are shown as the mean (± S.D.) fold expression level relative to untreated controls (set at 1). *D*, sequence of a known SBR within the human *BIK* promoter ([@B3]) compared with a putative Smad-binding element within the human *PUMA* promoter. The putative *PUMA* SBR at position −1923 to −1885 was analyzed by ChIP using specific primers encompassing this region. *E*, ChIP assay for Smad recruitment to the endogenous *PUMA* promoter in CA46 cells cultured with and without TGF-β for 1 h. Input lanes are from 10% of samples used in the IPs performed with control IgG, Smad3, and Smad4 antibodies.](zbc0101338940003){#F3}

We next analyzed the activity of a luciferase promoter reporter construct containing ∼2 kb of the 5′ region upstream of the *PUMA* transcription start site ([@B31]). The *PUMA* promoter construct was constitutively active in CA46 BL cells and could not be further induced by the addition of exogenous TGF-β ([Fig. 4](#F4){ref-type="fig"}*A*), suggesting that the endogenous level of TGF-β signaling in these cells may be sufficient for maximal activity of the isolated promoter region. We therefore tested whether inhibition of basal TGF-β signaling using 10 μ[m]{.smallcaps} of the ALK5 inhibitor SB-431542 would affect *PUMA* promoter activity ([Fig. 4](#F4){ref-type="fig"}*B*). We observed an approximate 50% decrease in luciferase activity following SB-431542 treatment, indicating that TGF-β signaling is required for maximal promoter activity.

![**hPUMA promoter SBR luciferase reporter constructs.** *A* and *B*, transient transfection of CA46 BL cells with control reporter vector pBV-luciferase (pBV-luc) or pBV containing the human *PUMA* promoter sequence spanning ∼2 kb upstream from the transcription start site (pBV-*PUMA* FragE ([@B31])). Transfected cells were treated with 5 ng/ml TGF-β (*A*) or 10 μ[m]{.smallcaps} SB-431542 (*B*) as indicated. *C*, wild type and mutant SBE reporter plasmids were generated by cloning 2× concatemerized oligonucleotides of the sequences shown into the pGL3-promoter vector (Promega). *D* and *E*, the wild type SBE (pGL3--2×WT SBE) and the mutant SBE (pGL3--2xMut SBE) reporter constructs were assayed following exogenous TGF-β addition (*D*) or addition of SB-431542 (*E*) as indicated. *F* and *G*, CAGA~12~ (*F*) or pGL3--2×WT SBE (*G*) constructs were transfected into CA46 cells with either nonsilencing vector (*ns*) or shRNA vector targeting Smad4. After 48 h, the transfections were left untreated or treated with 5 ng/ml TGF-β. Transfection results throughout are expressed as the means (± S.D.) (*n* = 3) luciferase reporter activity relative to untreated control samples (set at 1). All data shown are normalized to either co-transfected *Renilla* luciferase or β-galactosidase activity.](zbc0101338940004){#F4}

To examine the activity of the potential Smad-binding region more directly, we generated firefly luciferase reporter constructs containing concatemerized (2×) versions of wild type and mutant sequences shown in [Fig. 4](#F4){ref-type="fig"}*C*. Consistent with the 2-kb promoter fragment, the 2× wild type SBE sequence was active in CA46 cells. This activity was dependent on the consensus SBEs because mutation of the sequence **agac**tct**gtct** to **atat**tct**atat** reduced reporter activity to near basal levels ([Fig. 4](#F4){ref-type="fig"}*D*). Inhibition of endogenous TGF-β signaling also reduced activity of the 2× wild type SBE reporter ([Fig. 4](#F4){ref-type="fig"}*E*).

We next transiently transfected a shRNA construct targeting Smad4 to determine whether Smad4 is required for *PUMA* promoter activity. Because BL cells are renowned for their low transfection rate, we monitored efficacy of Smad4 knockdown by inhibition of the Smad4 dependent CAGA~12~-luciferase reporter response to TGF-β addition ([Fig. 4](#F4){ref-type="fig"}*F*). We were able to achieve a partial inhibition of CAGA~12~ activity and likewise observed a small but significant decrease in *PUMA* activity ([Fig. 4](#F4){ref-type="fig"}*G*). Taken together, these findings indicate that regulation of the *PUMA* promoter by TGF-β signaling is most likely dependent on Smad binding at the SBR at positions −1923 to −1885 and that proper regulation of the endogenous gene depends on the correct repressive chromatin context.

#### PUMA Knockdown Retards TGF-β-induced Apoptosis

To determine the functional consequence of PUMA induction by TGF-β, we used lentiviral transduction of shRNA constructs to stably knockdown PUMA in BL30 cells. Transducing BL30 cells with a combination of two commercially available shRNA constructs (shRNA1 + 2) reduced the basal and TGF-β-inducible *PUMA* levels to below the background levels observed in the control line ([Fig. 5](#F5){ref-type="fig"}*A*). Two PUMA knockdown stable cell pools (shRNA1 + 2\#1 and shRNA1 + 2\#2) were analyzed for apoptosis induction by TGF-β using propidium iodide staining and flow cytometry. Knockdown of PUMA resulted in a significant reduction in the amount of apoptosis induction by TGF-β after 24 h of treatment ([Fig. 5](#F5){ref-type="fig"}*B*). We noted, however, that at later time points (48 h) there was little discernable difference between apoptosis induction in control *versus* PUMA knockdown cell lines (data not shown). We therefore carried out a more detailed kinetic analysis of early apoptosis induction using PARP cleavage as a measure ([Fig. 5](#F5){ref-type="fig"}*C*, *top panel*). The Western blots revealed that although all lines retained equivalent TGF-β signaling, shown by equal levels of phosphorylation of the receptor regulated Smad2, the apoptotic response in PUMA knockdown lines was retarded when compared with the control line, 22 and 18% PARP cleavage in the knockdown lines after 8 h of treatment compared with 50% (summarized in the graph shown in [Fig. 5](#F5){ref-type="fig"}*C*, *bottom panel*).

![**Knockdown of PUMA retards TGF-β-induced apoptosis in BL lines.** *A*, independent stable cell lines expressing nonsilencing (Scrambled) or shRNAs targeted against *PUMA* (shRNA1 + 2\#1 and shRNA1 + 2\#2) were generated by lentiviral infection of BL30 cells. Real time qPCR was used to demonstrate the efficacy of knockdown of *PUMA* in stable BL30 cells in untreated cells and cells treated for 2 h with TGF-β. Mean relative amounts of *PUMA* RNA are expressed after normalization to 18 S rRNA levels. *B*, determination of apoptosis by propidium iodide (*PI*) staining and flow cytometry following 24 h TGF-β treatment of the cell lines described in *A*. Statistical analysis was performed using Student\'s *t* test. *C*, Western blot analysis of apoptosis (PARP) and TGF-β signaling (p-Smad2) in BL30 stable cell lines described in *A* and *B* during a time course of TGF-β treatment. A Western blot for actin is included as a loading control. The amount of cleaved PARP as a percentage of total PARP determined by densitometry is indicated above each lane and is summarized in the graph shown below.](zbc0101338940005){#F5}

#### TGF-β Induces Apoptosis and PUMA Expression in Eμ-Myc Murine Lymphoma Lines

Given that *PUMA* expression levels in the stable knockdown cell lines were reduced to below the basal levels detected in untreated controls ([Fig. 5](#F5){ref-type="fig"}*A*), the lack of any significant effect on the percentage of apoptotic cells at later time points is unlikely to be a consequence of the incomplete inhibition of PUMA induction in response to TGF-β. However, to exclude this possibility, we extended our study to compare wild type and *Puma* null murine B-lymphoma cells. Eμ-*Myc* murine lymphoma lines are a model of BL. We first determined whether isolated wild type Eμ-*Myc* lymphoma cells undergo apoptosis in response to TGF-β addition *in vitro*. Annexin V staining of Eμ-*Myc* cells revealed TGF-β-induced cell death after 24 h of treatment ([Fig. 6](#F6){ref-type="fig"}*A*). Apoptosis was confirmed by cleavage of PARP in TGF-β-treated wild type lymphoma cells ([Fig. 6](#F6){ref-type="fig"}*B*). Cell death in response to TGF-β was dependent on the TGF-β type I receptor ALK5 because pretreatment of lymphoma cells with SB-431542 inhibited death induced by TGF-β but had no effect on the cellular response to the DNA damage-inducing agent etoposide ([Fig. 6](#F6){ref-type="fig"}, *C* and *D*). Apoptosis was inhibited by overexpression of BCL-2 in murine lymphoma lines, indicating the involvement of the intrinsic apoptosis pathway ([Fig. 6](#F6){ref-type="fig"}, *E* and *F*). In addition, TGF-β treatment resulted in induction of *Puma* shown by quantitative RT-PCR ([Fig. 6](#F6){ref-type="fig"}*G*) and by Western blot ([Fig. 6](#F6){ref-type="fig"}*H*). These data indicate that wild type murine Eμ-*Myc* lymphoma cells mimic the response of human BL cell lines to TGF-β and undergo ALK5-dependent intrinsic apoptosis involving PUMA induction.

![**Murine Eμ-*Myc* lines are sensitive to TGF-β-induced apoptosis.** *A*, murine Eμ-*Myc* cell lines were analyzed by annexin V staining and flow cytometry for their response to TGF-β treatment (24 h). *B*, Western blot analysis of lysates from Eμ-*Myc* cell lines showing cleavage of PARP following 12 h of treatment with TGF-β. *C* and *D*, murine Eμ-*Myc* line 4 (*C*) and line 8 (*D*) were treated for 24 h with TGF-β or etoposide (5 μg/ml) in the presence or absence of a TGF-β RI (ALK5) inhibitor, SB-431542 (*SBi*, 10 μ[m]{.smallcaps}). Apoptosis induction was determined by annexin V staining and flow cytometry and is expressed as the mean (± S.D.) percentage induction above background levels. *E* and *F*, Eμ-*Myc* cell lines stably transfected with empty vector (pMIH) or Bcl-2 expressing vector (pMIH-Bcl-2) were analyzed by Western blot for Bcl-2 expression (*E*) and by annexin V staining (*F*) for susceptibility to TGF-β induced apoptosis following 24 h of treatment. *G*, wild type Eμ-*Myc* cell lines were left untreated or treated with TGF-β for 2 h and analyzed by qRT-PCR for *Puma* mRNA expression levels. The results are expressed as the mean fold mRNA level relative to the untreated control. *H*, Western blot analysis of PUMA expression in untreated (*Con*) wild type Eμ-*Myc* lines or lines treated for 6 h with TGF-β. A blot for tubulin is included as a loading control. *DMSO*, dimethyl sulfoxide.](zbc0101338940006){#F6}

#### PUMA Is Required for Efficient Apoptosis Induction in Eμ-Myc Lymohoma Lines

shRNA knockdown of PUMA in human BL cell lines delayed the onset of apoptosis in response to TGF-β ([Fig. 5](#F5){ref-type="fig"}*C*). We observed a similar correlation in the murine Eμ-*Myc* line 16, which had slower *Puma* RNA induction after TGF-β addition ([Fig. 7](#F7){ref-type="fig"}*A*) and lower levels of apoptosis by 12 h of TGF-β treatment ([Fig. 7](#F7){ref-type="fig"}*B*). However, to definitively investigate the role of PUMA in this response, we compared the response of wild type Eμ-*Myc* cell lines with *Puma* null lines (*Puma*^−/−^) to TGF-β. All lines responded to TGF-β because they showed similar levels of Smad2 phosphorylation following exogenous TGF-β addition ([Fig. 7](#F7){ref-type="fig"}*C*). When the effects of TGF-β treatment were directly compared in wild type *versus Puma* null cells, there were significantly fewer apoptotic *Puma* null cells than apoptotic wild type cells at early time points following exposure to TGF-β ([Fig. 7](#F7){ref-type="fig"}*D*) but not at later time points ([Fig. 7](#F7){ref-type="fig"}*E*), thus confirming the data obtained in human BL lines. PUMA is therefore selectively required for efficient, rapid TGF-β-induced apoptosis.

![**Eμ-*Myc* cell lines derived from *Puma*^−/−^ mice exhibit a delayed apoptotic response to TGF-β.** *A*, kinetics of TGF-β-mediated *Puma* RNA induction in wild type Eμ-*Myc* lymphoma lines as determined by qPCR. *B*, early kinetics of apoptosis induction in wild type Eμ-*Myc* lymphoma lines as measured by annexin V staining. *C*, Western blot analysis of TGF-β signaling (pSmad2) and PUMA expression in WT and *Puma* null (*Puma*^−/−^) Eμ-*Myc* lymphoma lines in uninduced or induced conditions (6 h of treatment with TGF-β). A blot for total Smad2/3 is included as a loading control. *D* and *E*, apoptosis induction above background in lymphoma lines derived from WT (*n* = 4) and homozygous *Puma* null (*Puma*^−/−^) (*n* = 4) mice following 6 h (*D*) and 24 h (*E*) of treatment with TGF-β. Apoptosis induction above background was determined by annexin V staining and flow cytometry. The mean apoptosis values are shown as *bars*, and the *p* values were determined by Mann-Whitney statistical analysis.](zbc0101338940007){#F7}

DISCUSSION
==========

In this study we demonstrate a direct link between pro-apoptotic TGF-β signaling and transcriptional up-regulation of the apoptosis activator PUMA in c-Myc-driven B-cell lymphomas. PUMA was required for the effective, early induction of apoptosis in both human and murine lymphomas, but its induction does not require c-Myc activity. The involvement of PUMA in this process was demonstrated by stable knockdown of PUMA in human BL, but to be confident that we could assess the effect of complete lack of PUMA on TGF-β-induced apoptosis, we extended our analysis to compare Eμ-*Myc* lymphomas derived from *Puma* null and wild type mice. We believe this is the first demonstration that murine Eμ-*Myc* lymphomas are susceptible to TGF-β-induced apoptosis. Stroma-derived TGF-β from infiltrating immune cells has previously been reported to mediate a tumor suppressor function *in vivo* by inducing senescence of Eμ-*Myc* lymphoma cells ([@B32]). Our data suggest that in addition to senescence, TGF-β expressed in the tumor microenvironment would also be likely to induce ALK5-dependent apoptosis of malignant cells.

We report that a complete loss of PUMA in knock-out Eμ-*Myc* cells and knockdown of PUMA in human BL cells delay cell death but do not ultimately prevent cells from undergoing apoptosis. This observation is consistent with the idea that PUMA has a role in priming cells for apoptosis as part of a polygenic apoptotic response that may have a role in "sensing" the apoptotic signal ([@B33]). As well as PUMA activation, the apoptotic program involves the early activation of BIK in human cells followed by down-regulation of BCL-X~L~ ([@B3]). Such changes in expression levels of the other BCL-2 family members presumably are sufficient to induce apoptosis, albeit with slower kinetics. As predicted previously, we have seen no TGF-β-dependent activation of BIK in mouse cells because the Smad-binding element identified within the human BIK promoter is not conserved (Ref. [@B3] and [Fig. 3](#F3){ref-type="fig"}). BCL-X~L~, however, is down-regulated in response to TGF-β in murine Eμ-*Myc* lymphoma cells.[^6^](#FN6){ref-type="fn"} This suggests that loss of BCL-X~L~ function may ultimately be sufficient in murine lymphoma to induce apoptosis. but we cannot exclude the possibility that other BH3-only sensitizers might also be induced in response to TGF-β in the mouse.

The mechanism of PUMA induction by TGF-β in this system requires some further analysis. We have determined that *PUMA* is induced even in the presence of protein synthesis inhibitors, demonstrating that *de novo* protein synthesis is not required for *PUMA* transcriptional up-regulation in BL cells and also that *in vivo*, activated Smad3/Smad4 is recruited directly to a SBR within the endogenous promoter. Constitutive activity of the isolated putative Smad-binding region was dependent on consensus SBE sequences in transient transfection assays, and it was partially inhibited by blocking endogenous TGF-β signaling and lowering Smad4 levels; however, exogenous addition of ligand did not induce its activity. These data suggest that chromatin structure and/or transcriptional repressors may be important for correct regulation of the endogenous gene.

The induction of PUMA-mediated apoptosis by TGF-β superfamily members has been described previously in oligodendrocytes (induced by activin A but not by TGF-β) and by TGF-β in a gastric cancer cell line. In both cases, however, elevated PUMA levels were dependent on p53 family members. A p53 family inhibitor pifithrin-α blocked activin A-induced apoptosis of oligodendrocytes ([@B34]), whereas TGF-β-induced apoptosis of SNU-16 gastric cancer cells was due to the induction of p73, which presumably bound p53 consensus sequences on the *PUMA* promoter ([@B35]). In these studies, there was no evidence that Smads were recruited directly to the *PUMA* promoter as detected in BL cells. However, it is possible that a p53 family member might still be involved in TGF-β-induced regulation of PUMA in our system by acting as co-activators with the Smad proteins. Smads are regulated by numerous post-translational modifications and cooperate with many other transcription factors (including the p53 family) to regulate gene transcription, thus ensuring that their function is highly context dependent ([@B6]). p53 and p73, for example, directly bind Smads 2 and 3 and can stabilize Smad-DNA complexes on specific gene promoters ([@B36]). It would seem unlikely that p53 is involved in TGF-β/Smad activation of the *PUMA* promoter because all but one of the BL cell lines used in this study express mutant p53 (BL2 cells express wild type p53 ([@B37])). Transcripts of p73 are expressed in BL cells but are not increased by TGF-β treatment.^6^

So far, direct activation of *PUMA* by TGF-β has been demonstrated in B-cell subsets (lymphomas and human primary centroblasts) but not in murine embryonic fibroblasts or HaCaT epithelial cells. The reason for the selective response in certain cell types is currently unclear. It is possible that the proteome of B-cells uniquely allows PUMA activation in response to TGF-β. The panel of BL cells examined here lack expression of SLUG, a transcription factor involved in the repression of PUMA transcription.^6^ Expression of SLUG in hematopoietic progenitor cells is responsible for protecting progenitor cells from DNA damage-induced apoptosis by repressing p53-mediated *PUMA* transcription ([@B38]). TGF-β may be able to induce *PUMA* in B-cells by virtue of its lack of repression. Another possibility is that *PUMA* is regulated by a B-cell-specific transcription factor in conjunction with TGF-β-activated Smads.

A study published during the preparation of this manuscript implicates the activation status of B-cells as a factor in PUMA production, with PUMA being involved in the regulation of antigen specific memory B-cells both *in vitro* and *in vivo*. PUMA protein expression was detected in histological sections of human lymph nodes, potentially as a result of antigenic stimulation, because stimulation of cells *in vitro* with the mitogens *Staphylococcus aureus* Cowan or LPS, or alternatively following ligation of the B-cell receptor or CD40, all resulted in up-regulation of PUMA. Provided sufficient pro-survival signals are received to maintain BCL-X~L~ levels, the effect of PUMA induction in this system is negated ([@B26]). The mechanism of PUMA induction was not identified by Clybouw *et al.* ([@B26]) but was determined to be independent of p53 because p53^−/−^ B-cells produced similar levels of PUMA to wild type cells.

Given our finding that *PUMA* is induced *in vitro* by TGF-β treatment of centroblasts ([Fig. 2](#F2){ref-type="fig"}) and that active, phosphorylated Smad2 is detectable throughout the germinal center ([@B3]), we can speculate that PUMA detected in the tonsil sections could result from TGF-β signaling. This may arise as a result of the establishment of an activation-induced TGF-β-autocrine feedback loop ([@B39]). There are several lines of evidence to support this hypothesis. TGF-β mRNA is detectable in both resting and activated B-cells ([@B40]). Stimulation of human tonsil cells with *S. aureus* Cowan does not significantly affect TGF-β mRNA levels but does result in a 7-fold increase in TGF-β protein secretion ([@B41]). Similarly, LPS treatment of murine splenocytes induces the production of bioactive TGF-β ([@B42]). The induction of TGF-β in activated B-cells is thought to limit the expansion of the activated population. Without this autoregulatory feedback loop severe autoimmunity develops ([@B43], [@B44]). Our data presented here indicate that regulation of PUMA plays a role in the apoptotic response of B-cells exposed to TGF-β and suggest that this may play a role in the efficient control of activated B-cell proliferation. This notion may provide an explanation for the elevated levels of IgA observed in *Puma* null mice ([@B45]) because IgA class switching is promoted by TGF-β ([@B46]). The intriguing possibility that activation-induced PUMA production occurs because of an autocrine TGF-β/ALK5/Smad pathway and the relative role, mechanisms, and kinetics of regulation of BCL-X~L~ and other BCL-2 family members in B-cell survival warrants further investigation.
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